Infant girl develops bulging sacral massA 3-week-old female presented to the emergency department with a 3-day history of a progressively enlarging, erythematous, seemingly painful lump on her back.
Dinutuximab wins FDA approval for neuroblastomaFDA has approved dinutuximab (Unituxin, United Therapeutics) in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2 (IL-2), and 13-cis-retinoic acid (RA), for the treatment of high-risk pediatric neuroblastoma patients who achieve at least a partial response to prior first-line multiagent, multimodality therapy.
First therapy for pediatric high-risk neuroblastoma approved by FDAFDA approved dinutuximab (Unituxin, United Therapeutics) as part of first-line therapy for pediatric patients with high-risk neuroblastoma, a type of cancer that most often occurs in young children.
FDA drug approvals-March 2015FDA actions in brief, breakthrough designation, recommended for approval, priority review, fast-track designations